Mount Yale Investment Advisors LLC Has $677,000 Holdings in ResMed Inc. (NYSE:RMD)

Mount Yale Investment Advisors LLC trimmed its holdings in ResMed Inc. (NYSE:RMD) by 3.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,539 shares of the medical equipment provider’s stock after selling 123 shares during the period. Mount Yale Investment Advisors LLC’s holdings in ResMed were worth $677,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of ResMed by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 17,743,457 shares of the medical equipment provider’s stock valued at $3,052,229,000 after acquiring an additional 173,635 shares during the period. Bank of New York Mellon Corp lifted its position in ResMed by 51.4% during the second quarter. Bank of New York Mellon Corp now owns 5,772,761 shares of the medical equipment provider’s stock worth $1,105,022,000 after purchasing an additional 1,959,642 shares during the period. Los Angeles Capital Management LLC grew its stake in ResMed by 48.3% during the second quarter. Los Angeles Capital Management LLC now owns 740,226 shares of the medical equipment provider’s stock worth $141,694,000 after buying an additional 241,195 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in ResMed by 15.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 698,905 shares of the medical equipment provider’s stock valued at $120,225,000 after buying an additional 95,689 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of ResMed by 19.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 661,717 shares of the medical equipment provider’s stock valued at $126,670,000 after buying an additional 107,279 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Michael J. Farrell sold 14,683 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $192.97, for a total transaction of $2,833,378.51. Following the completion of the transaction, the chief executive officer now directly owns 440,799 shares in the company, valued at $85,060,983.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Brett Sandercock sold 1,000 shares of the stock in a transaction on Monday, July 8th. The shares were sold at an average price of $194.35, for a total transaction of $194,350.00. Following the completion of the sale, the chief financial officer now directly owns 90,056 shares in the company, valued at $17,502,383.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael J. Farrell sold 14,683 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $192.97, for a total transaction of $2,833,378.51. Following the completion of the transaction, the chief executive officer now owns 440,799 shares in the company, valued at approximately $85,060,983.03. The disclosure for this sale can be found here. In the last three months, insiders have sold 102,931 shares of company stock valued at $22,644,807. 1.21% of the stock is currently owned by company insiders.

ResMed Stock Performance

NYSE:RMD opened at $246.18 on Tuesday. The stock’s 50-day moving average is $227.73 and its 200-day moving average is $209.99. ResMed Inc. has a 1-year low of $132.24 and a 1-year high of $255.18. The company has a current ratio of 2.59, a quick ratio of 1.69 and a debt-to-equity ratio of 0.14. The stock has a market cap of $36.17 billion, a P/E ratio of 37.82, a price-to-earnings-growth ratio of 2.50 and a beta of 0.69.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.05. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.22 billion. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.60 EPS. Equities research analysts anticipate that ResMed Inc. will post 8.92 earnings per share for the current year.

ResMed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 19th. Investors of record on Thursday, August 15th were given a dividend of $0.53 per share. This is a positive change from ResMed’s previous quarterly dividend of $0.48. This represents a $2.12 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend was Thursday, August 15th. ResMed’s dividend payout ratio (DPR) is currently 32.57%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on RMD. Wolfe Research reissued an “underperform” rating and issued a $180.00 price objective on shares of ResMed in a research note on Wednesday, September 18th. StockNews.com lowered ResMed from a “buy” rating to a “hold” rating in a research note on Friday, August 30th. Royal Bank of Canada upped their price objective on ResMed from $204.00 to $206.00 and gave the stock a “sector perform” rating in a research report on Friday, August 2nd. Citigroup cut ResMed from a “buy” rating to a “neutral” rating in a research report on Monday, June 24th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ResMed in a report on Wednesday, September 18th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $199.70.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.